BioFocus Enters Collaboration with Michael J. Fox Foundation
News Jul 14, 2011
BioFocus has announced that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.
Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test.
“We are delighted to have the opportunity to support The Michael J. Fox Foundation in its development of improved therapies for those living with Parkinson’s,” said Dr Kate Hilyard, VP Biological Sciences.
Dr Hilyard continued, “The collaboration will utilize BioFocus' biology platform that delivers drug discovery solutions through its experienced teams and state-of-the-art technologies”.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018